HK1245115A1 - 口腔奧曲肽與其他治療劑聯合應用 - Google Patents
口腔奧曲肽與其他治療劑聯合應用Info
- Publication number
- HK1245115A1 HK1245115A1 HK18104622.8A HK18104622A HK1245115A1 HK 1245115 A1 HK1245115 A1 HK 1245115A1 HK 18104622 A HK18104622 A HK 18104622A HK 1245115 A1 HK1245115 A1 HK 1245115A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combination
- therapeutic agents
- oral octreotide
- octreotide administered
- administered
- Prior art date
Links
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 title 1
- 108010016076 Octreotide Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229960002700 octreotide Drugs 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462090130P | 2014-12-10 | 2014-12-10 | |
| PCT/US2015/065006 WO2016094662A1 (en) | 2014-12-10 | 2015-12-10 | Oral octreotide administered in combination with other therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1245115A1 true HK1245115A1 (zh) | 2018-08-24 |
Family
ID=56108186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18104622.8A HK1245115A1 (zh) | 2014-12-10 | 2018-04-09 | 口腔奧曲肽與其他治療劑聯合應用 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US20160193285A1 (zh) |
| EP (2) | EP3229824A4 (zh) |
| AU (3) | AU2015360485B2 (zh) |
| CA (1) | CA2970519A1 (zh) |
| HK (1) | HK1245115A1 (zh) |
| IL (2) | IL252689B (zh) |
| MA (1) | MA41159A (zh) |
| WO (1) | WO2016094662A1 (zh) |
| ZA (1) | ZA201704026B (zh) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033611T2 (en) | 2008-09-17 | 2017-12-28 | Chiasma Inc | Pharmaceutical preparations and associated dosing procedures |
| AU2015360485B2 (en) | 2014-12-10 | 2020-06-25 | Amryt Endo, Inc. | Oral octreotide administered in combination with other therapeutic agents |
| CA2975599A1 (en) | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
| US10039801B2 (en) | 2016-02-16 | 2018-08-07 | Strongbridge Ireland Limited | Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use |
| KR102611788B1 (ko) | 2016-09-27 | 2023-12-12 | 카무러스 에이비 | 알킬 암모늄 edta 염을 포함하는 혼합물 및 제형 |
| EP3355188B1 (en) | 2017-01-31 | 2021-08-25 | OpenSynergy GmbH | Instrument display on a car dashboard by checking frames of a gui by a realtime os |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| WO2022251212A2 (en) * | 2021-05-25 | 2022-12-01 | Crinetics Pharmaceuticals, Inc. | Uses of a somatostatin modulator for the treatment of disease |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8701143A (nl) | 1986-05-27 | 1987-12-16 | Sandoz Ag | Farmaceutische preparaten. |
| GB9203769D0 (en) | 1992-02-21 | 1992-04-08 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US7803781B2 (en) * | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
| US20040185170A1 (en) * | 2003-03-21 | 2004-09-23 | Shubha Chungi | Method for coating drug-containing particles and formulations and dosage units formed therefrom |
| WO2005041901A2 (en) | 2003-11-03 | 2005-05-12 | Elixir Pharmaceuticals, Inc. | Therapeutics using somatostatin agonists |
| EP1682091B1 (en) | 2003-11-07 | 2017-03-29 | Camurus Ab | Compositions of lipids and cationic peptides |
| US20050232981A1 (en) | 2004-04-15 | 2005-10-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| US20070219131A1 (en) | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| US8541400B2 (en) | 2004-08-04 | 2013-09-24 | Camurus Ab | Compositions forming non-lamellar dispersions |
| US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| AR059423A1 (es) | 2006-02-09 | 2008-04-09 | Univ Maryland | Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2010020978A1 (en) | 2008-08-18 | 2010-02-25 | Oramed Pharmaceuticals Ltd | Methods and compositions for oral administration of proteins |
| HUE033611T2 (en) * | 2008-09-17 | 2017-12-28 | Chiasma Inc | Pharmaceutical preparations and associated dosing procedures |
| AR074603A1 (es) | 2008-12-15 | 2011-01-26 | Novartis Ag | Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit |
| AU2015360485B2 (en) | 2014-12-10 | 2020-06-25 | Amryt Endo, Inc. | Oral octreotide administered in combination with other therapeutic agents |
| CA2975599A1 (en) * | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
-
2015
- 2015-12-10 AU AU2015360485A patent/AU2015360485B2/en active Active
- 2015-12-10 US US14/965,318 patent/US20160193285A1/en not_active Abandoned
- 2015-12-10 EP EP15868039.7A patent/EP3229824A4/en not_active Withdrawn
- 2015-12-10 EP EP23206479.0A patent/EP4321213A3/en active Pending
- 2015-12-10 WO PCT/US2015/065006 patent/WO2016094662A1/en active Application Filing
- 2015-12-10 MA MA041159A patent/MA41159A/fr unknown
- 2015-12-10 CA CA2970519A patent/CA2970519A1/en active Pending
-
2017
- 2017-06-05 IL IL252689A patent/IL252689B/en unknown
- 2017-06-12 ZA ZA2017/04026A patent/ZA201704026B/en unknown
-
2018
- 2018-04-09 HK HK18104622.8A patent/HK1245115A1/zh unknown
- 2018-05-07 US US15/972,557 patent/US10682387B2/en active Active
-
2020
- 2020-05-07 US US16/868,958 patent/US20210077569A1/en not_active Abandoned
- 2020-09-24 AU AU2020239738A patent/AU2020239738A1/en not_active Abandoned
-
2021
- 2021-08-08 IL IL285440A patent/IL285440A/en unknown
-
2022
- 2022-07-11 US US17/861,996 patent/US20220339240A1/en not_active Abandoned
-
2023
- 2023-02-17 US US18/170,886 patent/US20230201302A1/en not_active Abandoned
- 2023-10-20 US US18/490,985 patent/US20240041973A1/en active Pending
-
2024
- 2024-01-25 AU AU2024200465A patent/AU2024200465A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3229824A4 (en) | 2018-07-11 |
| US20160193285A1 (en) | 2016-07-07 |
| AU2020239738A1 (en) | 2020-10-15 |
| AU2024200465A1 (en) | 2024-02-15 |
| AU2015360485B2 (en) | 2020-06-25 |
| US20190091285A1 (en) | 2019-03-28 |
| MA41159A (fr) | 2021-05-12 |
| IL285440A (en) | 2021-09-30 |
| US20220339240A1 (en) | 2022-10-27 |
| CA2970519A1 (en) | 2016-06-16 |
| WO2016094662A1 (en) | 2016-06-16 |
| EP4321213A3 (en) | 2024-05-15 |
| EP3229824A1 (en) | 2017-10-18 |
| US20240041973A1 (en) | 2024-02-08 |
| IL252689B (en) | 2021-09-30 |
| US20230201302A1 (en) | 2023-06-29 |
| EP4321213A2 (en) | 2024-02-14 |
| AU2015360485A1 (en) | 2017-06-29 |
| US20210077569A1 (en) | 2021-03-18 |
| ZA201704026B (en) | 2021-01-27 |
| IL252689A0 (en) | 2017-08-31 |
| US10682387B2 (en) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245115A1 (zh) | 口腔奧曲肽與其他治療劑聯合應用 | |
| IL250752A0 (en) | Device with compounds for conduction to lungs, oral mucosa and brain | |
| HK1245834A1 (zh) | 一種b細胞用於體內遞送治療劑 | |
| IL252601A0 (en) | A motorized tool for oral care | |
| GB201420039D0 (en) | System for training a user in administering a medicament | |
| IL250990A0 (en) | Materials for human care | |
| DK3229816T3 (en) | Proton-bindende polymerer til oral administration | |
| IL248855B (en) | S-pyralindole and its pharmaceutically acceptable salts for use in medicine | |
| IL248854A0 (en) | R-pyralindole and its pharmaceutically acceptable salts for use in medicine | |
| HK1223630A1 (zh) | 抗- 療法的實施與用量 | |
| GB201406172D0 (en) | Therapy and pharmaceutical composition | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| HUE045185T2 (hu) | Új terápiás vegyület és terápiában történõ alkalmazása | |
| EP3143036C0 (en) | PAR-1 BASED THERAPEUTIC CONJUGATES AND USES THEREOF | |
| GB201409653D0 (en) | Pyrrolobenzodiazepine therapeutic agents | |
| GB201616880D0 (en) | Compound for use in medicine | |
| HRP20182167T1 (hr) | Derivati benzilhidroksida, njihova priprava i njihova terapeutska uporaba | |
| TH1601006738A (th) | (s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค | |
| GB201409978D0 (en) | Novel compounds and their use in therapy |